13.8
흡입 마취제는 흡입 시 전신 마취를 유도하는 약물입니다. 이 약물은 GABA_A 수용체의 민감도를 높이거나 NMDA 수용체를 억제하여 중추 신경계 활동을 감소시킵니다. 흡입 가스의 농도를 변경하여 마취의 깊이를 빠르게 조절할 수 있습니다. 흡입 마취제의 일반적인 예로는…
흡입 마취제는 폐포와 조직을 가로질러 빠르게 확산되는 흡입 가스와 휘발성 액체를 통해 전신 마
취를 유도합니다.이러한 약제의 마취 효능은 최소 폐포 농도에 따라 달라집니다. 이러한 마취제의 분배에는 폐포 세척(wash-in)이 포함되며, 그 후 조직을 빠르게 흡수합니다.
이들은 가파른 용량-반응 곡선을 나타내며 알려진 길항제는 없는 좁은 치료 지표를 나타냅니다.
현대의 약제는 이소플루란(isoflurane), 데스플루란(desflurane), 세보플루란(sevoflurane)과 같은 휘발성 액체와 아산화질소(chlorus oxide)와 같은 가스를 포함합니다. 불연성, 비폭발성이며 폐기물을 최소화하기 위해 재순환 시스템을 통해 전달됩니다.
이러한 약제는 NMDA 수용체를 억제하는 아산화질소를 제외한 GABAA 수용체에 대한 GABA의 작용을 강화하여 뇌혈관 저항과 호흡 욕구를 감소시킵니다.
이러한 물질은 저혈압, 호흡기 자극 및 신독성과 같은 잠재적인 부작용이 있습니다. 할로겐화 탄화수소에 노출되면 생명을 위협하는 희귀 질환인 악성 고열이 유발될 수 있습니다.
특히 대부분의 흡입 마취제는 변경되지 않은 상태로 대기 중으로 방출되기 때문에 환경에 심각한 영향을 미칩니다.
View the full transcript and gain access to JoVE Core videos
Q1: How do inhalational anesthetics induce general anesthesia?
Inhalational anesthetics induce general anesthesia through inhaled gases and volatile liquids that diffuse rapidly across pulmonary alveoli into tissues. Most agents enhance GABA's action on GABAA receptors, decreasing central nervous system activity. Nitrous oxide uniquely inhibits NMDA receptors instead. The depth of anesthesia can be rapidly adjusted by changing the inhaled gas concentration.
Q2: What is minimum alveolar concentration and why does it matter?
Minimum alveolar concentration (MAC) is the measure of anesthetic potency, determining how much inhaled anesthetic is needed for effect. It varies based on patient factors like age, temperature, and concurrent drug use. Agents with lower MAC values are more potent. This metric helps clinicians select appropriate anesthetics and dosing for individual patients.
Q3: What are the main types of modern inhalational anesthetics?
Modern inhalational anesthetics include volatile liquids such as isoflurane, desflurane, and sevoflurane, plus gases like nitrous oxide. Isoflurane causes dose-dependent hypotension with a pungent odor. Desflurane offers rapid onset and recovery due to low blood solubility. Sevoflurane has low pungency and is preferred for pediatric inhalation induction.
Q4: What adverse effects are associated with inhalational anesthetics?
Inhalational anesthetics can cause hypotension, respiratory irritation, and organ toxicity including nephrotoxicity. Exposure to halogenated hydrocarbons may trigger malignant hyperthermia, a rare but life-threatening condition. Metabolism can generate toxic metabolites, prompting replacement with less toxic alternatives. These risks require careful patient selection and monitoring during anesthesia.
Q5: Why are inhalational anesthetics a concern for the environment?
Most inhalational anesthetics are released unchanged into the atmosphere as greenhouse gases, contributing to global warming and climate change. Their environmental persistence and potency as climate agents have prompted efforts to minimize their use and atmospheric release. This environmental impact influences anesthetic selection in clinical practice.
Q6: How are inhalational anesthetics distributed and delivered in the body?
Inhalational anesthetics distribute through alveolar wash-in followed by rapid tissue uptake. They exhibit steep dose-response curves and narrow therapeutic indices ranging from 2 to 4, with no known antagonists. Modern agents are delivered via recirculation systems to minimize waste. This distribution pattern allows rapid onset and offset of anesthetic effects.
Q7: What factors influence the selection of a specific inhalational anesthetic?
Selection involves balancing the patient's pathophysiology against the drug's side-effect profile. Clinicians consider factors like age, temperature, concurrent medications, and the procedure duration. Sevoflurane is preferred for pediatric patients due to low pungency, while desflurane suits short procedures. The goal is maintaining optimal brain partial pressure while minimizing adverse effects.